Side effects of bone-targeted therapies in advanced breast cancer

Breast Care

Volumn 9, Issue 5, 2014, Pages 332-336

  Domschke, Christoph ^a   Schuetz, Florian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adverse events; Bisphosphonates; Bone targeted agents; Breast cancer; Denosumab

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; DENOSUMAB; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; BONE METASTASIS; BONE TARGETED THERAPY; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER PATIENT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DENTAL PROCEDURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; MOLECULARLY TARGETED THERAPY; NEPHROTOXICITY; OSTEOCLAST; REVIEW; RISK FACTOR; SEVERE RENAL IMPAIRMENT; VITAMIN SUPPLEMENTATION;

EID: 84913618871     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000368844     Document Type: Review

References (60)

1. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
2. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-6249s.
3. Kinnane N: Burden of bone disease. Eur J Oncol Nurs 2007;11(suppl 2):528-531.
4. Pockett RD, Castellano D, McEwan P, et al.: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care 2010;19:755-760.
5. Sathiakumar N, Delzell E, Morrisey MA, et al.: Mortality following bone metastasis and skeletalrelated events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14:177-183.
6. Snedecor SJ, Carter JA, Kaura S, Botteman MF: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ 2013;16:19-29.
7. Smith HS: Painful osseous metastases. Pain Physician 2011;14:E373-E403.
8. Hird A, Zhang L, Holt T, et al.: Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases: a phase II study. Clin Oncol 2009;21:329-335.
9. Gnant M, Balic M, Petru E, et al.: Treatment of bone metastases in patients with advanced breast cancer. Breast Care 2012;7:92-98.
10. Ford JA, Jones R, Elders A, et al.: Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network metaanalysis. Eur J Cancer 2013;49:416-430.
11. Prommer EE: Toxicity of bisphosphonates. J Palliat Med 2009;12:1061-1065.
12. Diel IJ: Bisphosphonates in breast cancer patients with bone metastases. Breast Care 2010;5:306-311.
13. Rogers MJ, Watts DJ, Russell RG: Overview of bisphosphonates. Cancer 1997;80:1652-1660.
14. Boyce BF, Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-146.
15. Anandarajah AP, Schwarz EM: Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J Cell Bio chem 2006;97:226-232.
16. Diel IJ: Bone metastasis in breast cancer. Breast Care 2012;7:90-91.
17. Hagiwara M, Delea TE, Cong Z, Chung K: Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer 2014;22:103-113.
18. Prommer E: Palliative oncology: denosumab. Am J Hosp Palliat Care 2014;Epub ahead of print.
19. Candelaria-Quintana D, Dayao ZR, Royce ME: The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer. Breast Cancer Res Treat 2012;132:355-363.
20. Stopeck AT, Lipton A, Body JJ, et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
21. Anghel R, Bachmann A, Beksac M, et al.; American Society of Clinical Oncology; National Comprehensive Cancer Network: Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr 2013;125:439-447.
22. Fizazi K, Carducci M, Smith M, et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
23. Gartrell BA, Coleman RE, Fizazi K, et al.: Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. Eur Urol 2014;65:278-286.
24. Tanvetyanon T, Stiff PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
25. Fraunfelder FW, Fraunfelder FT: Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111:1275-1279.
26. Moore MM, Beith JM: Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust 2008;188:370-371.
27. Lenart BA, Lorich DG, Lane JM: Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358:1304-1306.
28. Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94: 1458-1468.
29. Smith MR, Egerdie B, Hernandez Toriz N, et al.: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755.
30. Smith MR, Saad F, Coleman R, et al.: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46.
31. Thiebaud D, Sauty A, Burckhardt P, et al.: An in vitro and in vivo study of cytokines in the acutephase response associated with bisphosphonates. Calcif Tissue Int 1997;61:386-392.
32. Wark JD, Bensen W, Recknor C, et al.: Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 2012;23:503-512.
33. Chen T, Berenson J, Vescio R, et al.: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1236.
34. Weiss HM, Pfaar U, Schweitzer A, et al.: Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008;36:2043-2049.
35. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-1393.
36. Edwards BJ, Usmani S, Raisch DW, et al.: Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project. J Oncol Pract 2013; 9:101-106.
37. Markowitz GS, Appel GB, Fine PL, et al.: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172.
38. Markowitz GS, Fine PL, Stack JI, et al.: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-289.
39. Jackson GH: Renal safety of ibandronate. Oncologist 2005;10(suppl 1):14-18.
40. Diel IJ, Bergner R, Grotz KA: Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-482.
41. Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
42. Berenson JR, Vescio RA, Rosen LS, et al.: A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001;7:478-485.
43. Markowitz GS, Fine PL, D'Agati VD: Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002;39:1118-1122.
44. Bergner R, Diel IJ, Henrich D, et al.: Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006;29:534-540.
45. Block GA, Bone HG, Fang L, et al.: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27:1471-1479.
46. Van Poznak CH, Von Roenn JH, Temin S: American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract 2011;7:117-121.
47. Lechner B, DeAngelis C, Jamal N, et al.: The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer 2014;22:1765-1771.
48. Body J-J, Lipton A, Henry D, et al.: Incidence of hypocalcemia among denosumab-treated patients enrolled in three registrational phase 3 trials. IBMS BoneKEy 9, Article number: 193(2012):S24-S25 1; doi:10.1038/bonekey.2012,193.
49. Milat F, Goh S, Gani LU, et al.: Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone 2013;55:305-308.
50. Kreutle V, Blum C, Meier C, et al.: Bisphosphonate induced hypocalcemia - report of six cases and review of the literature. Swiss Med Wkly 2014; 144:w13979.
51. Buonerba C, Caraglia M, Malgieri S, et al.: Calcitriol: a better option than vitamin D in denosumabtreated patients with kidney failure? Expert Opin Biol Ther 2013;13:149-151.
52. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376.
53. Marx RE: Pamidronate (Aredin) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-1117.
54. Jungnera L, Gallego L: Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 2008;66: 1516-1517.
55. Campisi G, Fedele S, Fusco V, et al.: Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 2014;10:257-275.
56. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB: RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 2011;19:2035-2040.
57. Wang X, Yang KH, Wanyan P, Tian JH: Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett 2014;7:1997-2002.
58. Epstein MS, Epstein JB, Ephros HD: The effects of osteoclast modifiers on the oral cavity: a review for prescribers. Curr Opin Support Palliat Care 2012;6:337-341.
59. Uyanne J, Calhoun CC, Le AD: Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am 2014;58:369-384.
60. De Iuliis F, Taglieri L, Amoroso L, et al.: Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Res 2014;34:2477-2480.